Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD
Jørgen Vestbo, Grant Waterer, David Leather, Courtney Crim, Nawar Diar Bakerly, Lucy Frith, Loretta Jacques, Catherine Harvey, Imran Satia, Ashley Woodcock, Salford Lung Study Investigators, Jørgen Vestbo, Grant Waterer, David Leather, Courtney Crim, Nawar Diar Bakerly, Lucy Frith, Loretta Jacques, Catherine Harvey, Imran Satia, Ashley Woodcock, Salford Lung Study Investigators
Abstract
Mortality after an admission for pneumonia is considerably higher than for an admission for an exacerbation in COPD patients recruited from usual clinical practice. A proper diagnosis in acute worsenings of symptoms in COPD is therefore important. https://bit.ly/3LyhnnC
Trial registration: ClinicalTrials.gov NCT01551758.
Conflict of interest statement
Conflict of interest: J. Vestbo received personal fees from GlaxoSmithKline plc., Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, congress attendance from Chiesi and holds a grant from Boehringer Ingelheim. G. Waterer received personal fees from GlaxoSmithKline plc. N. Diar Bakerly received grants and personal fees from GlaxoSmithKline plc., Novartis and Almirall/AstraZeneca, and congress attendance from Boehringer Ingelheim. I. Satia received personal fees from GlaxoSmithKline plc., consulting and speaker fees from AstraZeneca and Merck, grants from Merck, GlaxoSmithKline plc, fellowship from ERS Marie-Curie Award, E.J. Moran Campbell Early Career Award, Department of Medicine, McMaster, outside the submitted work. A. Woodcock received speaker fees and expenses from Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis; is chairman/shareholder of Reacta Healthcare and Axalbion, and Chairman of the Medicines Evaluation Unit. D. Leather, L. Frith, L. Jacques and C. Harvey are employees of GlaxoSmithKline plc. and hold shares in the company. C. Crim was an employee of GlaxoSmithKline plc. at the time of the study.
Figures
References
- Vogelmeier CF, Criner GJ, Martinez FJ, et al. . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017; 49: 1700214. doi:10.1183/13993003.00214-2017
- Hurst JR, Vestbo J, Anzueto A, et al. . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138. doi:10.1056/NEJMoa0909883
- Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalisation from pneumonia. A prospective study of a general population. Eur Respir J 1995; 8: 1694–1698. doi:10.1183/09031936.95.08101694
- Ernst P, Gonzalez AV, Brassard P, et al. . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–166. doi:10.1164/rccm.200611-1630OC
- Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3: CD010115.
- Müllerova H, Chigbo C, Hagan GW, et al. . The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106: 1124–1133. doi:10.1016/j.rmed.2012.04.008
- Lieberman D, Lieberman D, Gelfer Y, et al. . Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264–1270. doi:10.1378/chest.122.4.1264
- Vestbo J, Leather D, Diar Bakerly N, et al. . Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N Engl J Med 2016; 375: 1253–1260. doi:10.1056/NEJMoa1608033
- Dransfield MT, Crim C, Criner GJ, et al. . Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT. Ann Am Thorac Soc 2021; 18: 788–798. doi:10.1513/AnnalsATS.202002-096OC
- Waljee AK, Rogers MAM, Lin P, et al. . Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017; 357: j1415. doi:10.1136/bmj.j1415
Source: PubMed